加载中
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
收盘时
US$16.72
−US$0.07 · -0.42%
盘后
US$16.90
+US$0.18 · +1.08%
10月13日 17:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
日内区间
当前US$16.72
52周区间
当前US$16.72
盘中时间采用ET。市场数据可能有所延迟。
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
日内区间
当前US$16.72
52周区间
当前US$16.72
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 85.8万 USD | 63.6万 USD | — | — | — |
| 销货成本 | 9.2万 USD | 3950.7万 USD | 15万 USD | — | 10.9万 USD |
| 毛利 | 76.6万 USD | −3887.1万 USD | −15万 USD | — | −10.9万 USD |
| 研究与开发 | 1959.7万 USD | 4150.7万 USD | 5354.4万 USD | 4068.9万 USD | 2690.9万 USD |
| 销售、一般及管理费用 | 1432.5万 USD | 1832.5万 USD | 2538.8万 USD | 2719.5万 USD | 1873.9万 USD |
| 营业费用 | 2883万 USD | 2162.5万 USD | 7893.2万 USD | 6788.4万 USD | 4564.8万 USD |
| 利息收入 | 218.9万 USD | 421.6万 USD | 614.7万 USD | 196.3万 USD | 5.4万 USD |
| 利息支出 | — | — | — | — | 1万 USD |
| 折旧和摊销 | 9.2万 USD | 13.1万 USD | 15万 USD | 16.7万 USD | 10.9万 USD |
| 营业利润 | −2806.4万 USD | −6049.6万 USD | −7893.2万 USD | −6788.4万 USD | −4564.8万 USD |
| 净利润 | −897.8万 USD | −5777.5万 USD | −7456.4万 USD | −6665.4万 USD | −4701.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年2月6日 | 1:8 | — | — |
已生效 2026年2月6日
1:8
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI226.03万0.00%2.3万亿 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF54.48万0.00%954亿 USD0.05%US$232.54-0.42%
iShares Micro-Cap ETFIWC20.15万0.02%13.17亿 USD0.60%US$179.6-1.13%
Dimensional - US Small Cap ETFDFAS11.21万0.00%338.04亿 USD0.31%US$78.33+0.20%
U.S. Micro Cap Portfolio ETFDFMC9.89万0.00%75.44亿 USD0.43%US$57.78+0.14%
Avantis U.S. Small Cap Equity ETFAVSC2.62万—30.79亿 USD0.25%US$70.06+0.13%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.21万0.00%61.96亿 USD0.26%US$68.51+0.28%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.15万0.00%455.76亿 USD0.17%US$84.455+0.03%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
